AI Proteins

About

AI Proteins is a biotechnology company founded in late 2021 that focuses on the computational design of novel miniprotein therapeutics. By integrating synthetic biology, robotics, automation, and artificial intelligence, the company creates proteins with optimized drug-like properties. Their mission is to develop protein-based medicines that combine the benefits of small molecules and biologics. The company utilizes a proprietary platform for the rapid design of structurally precise miniproteins tailored for specific therapeutic targets. Their automated production system can generate up to 1,000 miniproteins weekly, which are then characterized to validate their structure and activity. AI Proteins is advancing its pipeline in oncology and has established partnerships for research in inflammation and metabolic diseases. Notable collaborations include a research agreement with Bristol Myers Squibb and a project with the University of Missouri focused on radioligand therapy.